Making myelin imaging better in brain diseases

IMPROMYND: Improving Myelin imaging for NeuroDegenerative disorders

In this study, Maastricht University, Eindhoven University of Technology and Philips propose in a collaborative effort to use improved MRI scans to detect changes in the myelin content of the brain in people with Multiple Sclerosis (MS). MS is a common disease that affects the brain, and can cause severe physical and mental symptoms. Our improved MRI technique can detect changes in the myelin content of the brain more quickly and accurately than current methods. We will use this technique to study 93 people with MS who are on high efficiency medication. We will then assess the results of our MRI scans in relationship with changes in the patients' cognitive and motor skills as assessed by a smartphone app. In addition to studying people with MS, we will also use our improved MRI technique to study healthy volunteers. This will help us to improve and refine our technique so that it can be used more effectively in the clinic. If our technique is successful, it could be used in the clinic to diagnose and monitor MS more effectively. It could also be used to study other neurodegenerative diseases and could have economic benefits by reducing the time needed for MRI scans.


Health~Holland would like you to follow these guidelines:

  • First paragraph: short summary of the whole project (see point 4) with a highlight on the (newly) established public private partnership. 
  • Second paragraph: introduction on the societal/economic impact and relevance of the health/disease/vital functioning/etc. and why innovation is necessary. Make use of numbers, statistics, or rankings to illustrate the relevance of the project to the lay public.
  • Third paragraph: explanation of the project’s approach and conceptualisation, and how this innovative solution will contribute to the previously described societal challenge(s).
  • Fourth paragraph: description of deliverables and, if the project is finished, an illustration of the (end)results.
Summary
We aim to apply improved MRI scans to detect changes in myelin content in MS patients. If successful, the technique could be used in the clinic for early diagnosis and therapy prediction and monitoring in MS and other neurodegenerative diseases. It could also have economic benefits by reducing scan time.
Technology Readiness Level (TRL)
1/2 - 3
Time period
48 months
Partners